Cardiac Biomarkers Market to Reach USD 24.1 Billion by 2034

Pune, India, November 2025 - According to the latest report by Exactitude Consultancy, the Global Cardiac Biomarkers Market is valued at USD 14.9 billion in 2024 and is projected to reach USD 24.1 billion by 2034, growing at a CAGR of 5.0% from 2025 to 2034. Increasing global prevalence of cardiovascular diseases (CVDs), along with growing adoption of advanced diagnostic assays and AI-based cardiac risk prediction, is driving strong market growth.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/49877

Key Takeaways
• Market Size (2024): USD 14.9 Billion
• Forecast (2034): USD 24.1 Billion
• CAGR (2025-2034): 5.0%
• Core Growth Drivers: Rising incidence of heart failure and myocardial infarction, rapid diagnostic testing innovations, and integration of machine learning in cardiac analysis.
• Leading Companies: Abbott Laboratories, Roche Diagnostics, Siemens Healthineers AG, Danaher Corporation, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., QuidelOrtho Corporation, and Becton, Dickinson and Company (BD).

Market Story
Cardiovascular diseases remain the leading cause of death globally, accounting for nearly 18 million deaths annually. Early and precise diagnosis is essential for reducing morbidity and mortality - a need that continues to fuel adoption of high-sensitivity cardiac biomarker assays across hospitals and diagnostic laboratories.

Key biomarkers such as troponins (cTnI, cTnT), creatine kinase-MB (CK-MB), B-type natriuretic peptide (BNP), and myoglobin are critical tools for identifying myocardial injury, heart failure, and ischemic conditions.
Technological advancements have introduced multiplex testing panels and lab-on-a-chip diagnostics, enabling simultaneous detection of multiple cardiac markers within minutes. Additionally, AI and predictive analytics are being integrated into cardiac biomarker platforms to enhance clinical decision-making and risk stratification for personalized patient management.
The growing shift toward point-of-care (POC) testing and home-based cardiac diagnostics is also expanding accessibility, especially in emerging economies.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/49877/cardiac-biomarkers-market

Market Segmentation
By Biomarker Type:
• Troponins (cTnI, cTnT)
• Creatine Kinase-MB (CK-MB)
• B-Type Natriuretic Peptide (BNP) & NT-proBNP
• Myoglobin
• Others (D-dimer, CRP, H-FABP)

By Application:
• Myocardial Infarction
• Heart Failure
• Acute Coronary Syndrome (ACS)
• Atherosclerosis
• Others

By Location of Testing:
• Point-of-Care Testing
• Laboratory Testing

By End-User:
• Hospitals
• Diagnostic Laboratories
• Ambulatory Care Centers
• Research Institutes

By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Recent Developments
• 2025: Abbott launched its next-gen high-sensitivity troponin assay integrated with cloud-based cardiac monitoring software.
• 2024: Roche Diagnostics introduced a multiplex cardiac biomarker panel compatible with digital lab automation systems.
• 2024: Siemens Healthineers partnered with AI developers to create machine-learning algorithms for personalized cardiac risk analysis.
• 2023: Danaher Corporation expanded its cardiac diagnostics portfolio by acquiring an innovative POC biosensor startup.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=49877

Expert Insight
"Cardiac biomarkers are at the center of precision cardiology, enabling early detection and faster intervention," said Irfan Tamboli, Business Development Executive at Exactitude Consultancy.
"The integration of AI, biosensors, and multiplex assays is transforming how cardiovascular diseases are detected and managed across all levels of care."

Regional Outlook
• North America leads with more than 40% share, driven by high healthcare spending, advanced diagnostic infrastructure, and growing preventive screening programs.
• Europe follows closely, focusing on early cardiac risk prediction and adoption of lab automation in hospitals.
• Asia Pacific is expected to witness the fastest growth (CAGR above 6.1%) due to an expanding cardiac patient population and rising diagnostic investments in China and India.
• Latin America & Middle East are emerging markets showing increased demand for portable diagnostic devices and telecardiology solutions.

Conclusion
The Cardiac Biomarkers Market is at the forefront of modern cardiology, providing critical insights for early diagnosis, risk assessment, and treatment optimization. As healthcare systems worldwide embrace precision diagnostics and data-driven care, cardiac biomarkers will continue to play a pivotal role in reducing the global cardiovascular disease burden.

This report is also available in the following languages : Japanese (心臓バイオマーカー市場), Korean (심장 바이오마커 시장), Chinese (心脏生物标志物市场), French (Marché des biomarqueurs cardiaques), German (Markt für kardiale Biomarker), and Italian (Mercato dei biomarcatori cardiaci), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/49877

Our More Reports:

Critical Illness Insurance Market
https://exactitudeconsultancy.com/reports/49887/critical-illness-insurance-market

Neurorehabilitation Gaming Systems Market
https://exactitudeconsultancy.com/reports/49889/neurorehabilitation-gaming-systems-market

Wearable Ambulatory Monitoring Devices Market
https://exactitudeconsultancy.com/reports/49891/wearable-ambulatory-monitoring-devices-market

Asthma Copd Drugs Market
https://exactitudeconsultancy.com/reports/49893/asthma-copd-drugs-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.